BINDING AFINITY OF ANTIBODY MONOCLONAL TRASTUZUMAB AND HUMAN EPIDERMAL RECEPTOR TYPE-2 OVEREXPRESSED BY MAGLINAT OVARIUM TUMOR
Daftar Isi:
- Malignant ovarian tumor is the fourth most common malignancy in woman and the second most gynecological malignancy next to the endometrial carcinoma. High morbidity and mortality rates of the malignant ovarian tumor are mostly caused by the inability to detect an early stage of this malignancy. Almost 65-70% cases of ovarian tumor are found on later stage, with survival rate of about 5-50%. Human Epidermal Receptor (HER-2) is an epidermal growth factor receptor found on the surface of ovarium cells. Interaction between HER-2 with monoclonal antibody (mAb) has been an approach for diagnosis associated with specific interaction which is more targeted on molecule target. Trastuzumab is a humanized mAb which has amino acid structure similar to that of human mAb amino acid. The aim of this study was to analyse binding affinity of interaction between trastuzumab and HER-2 receptor overexpressed by malignant ovarian tumor. The experiment's results would be used as a basic consideration for the use of trastuzumab as molecular carrier for specific targeted contrast agent in Magnetic Resonance Imaging (MRI) procedure for maglinant ovarium tumor. This research covered descriptive study of trastuzumab radiolabeling and experimental design of corellational study to evaluate interaction between trastuzumab and HER-2 overexpressed by malignant ovarium tumor cell-lines. The malignant ovarian tumor cell-lines, SKOV-3 provided by LAPTIAB-BBPT, were treated with 125 Iradiolabeled trastuzumab. The in vitro interaction between trastuzumab and HER-2 was analysed by using Scatchard formula. Analysis result gave the value of maximum binding capacity, Bmax and discotiation constant, Kd were 4x10-7 M and 9,17x10-9 M respectively. It can be concluded that there was a strong interaction between trastuzumab with HER-2 which was expressed by malignant ovarian tumor.Keywords: Malignant ovarian tumor, HER-2, Monoclonal antibody, Trastuzumab, 125I, , Binding affinity.